Table 5 Echocardiographic features in the PULSE cohort compared to pSLE patients in the USA
PULSE subgroup who underwent echocardiography (n = 23) | Total cohort (n = 93) | Chang et al. (n = 297) | |
|---|---|---|---|
Reduced LVEF % (n) | 13 (3) | 3.2 (3) | NR |
Markedly reduced LVEF % | 2.2 (1) | 1 (1) | NR |
Left ventricular hypertrophy % (n) | 39 (9) | 9.8 (9) | NR |
Right ventricular hypertrophy % (n) | 13 (3) | 3.2 (3) | NR |
Right ventricular dilation % (n) | 9 (2) | 2.1 (2) | NR |
Cardiomyopathy % (n) | 4 (1) | 1.1 (1) | NR |
Effusion % (n) | 65 (15) | 16.1 (15) | 10.4 (31) |
Tamponade | 6.7 (3) | 3.2 (3) | 0.7 (2) |
Effusion requiring intervention % (n) | 30 (7) | 7.5 (7) | 1.5 (4) |
Valvular dysfunction % (n) | 44 (10) | 10.8 (10) | 9.1 (27) |
Aortic regurgitation % (n) | 4 (1) | 1.1 (1) | NR |
Pulmonary regurgitation % (n) | 4 (1) | 1.1 (1) | NR |
Tricuspid regurgitation % (n) | 4 (1) | 1.1 (1) | NR |
Mitral regurgitation % (n) | 4 (1) | 1.1 (1) | NR |
Multiple valves % (n) | 26 (6) | 6.4 (6) | NR |
Severe valvular dysfunction % (n) | 26 (6) | 6.4 (6) | NR |